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Since the introduction of radionuclides into 
clinical medicine, a number of specific tests have been 
designed to test thyroid function and to diagnose dis-
eases of the thyroid gland. 
These studies can be broadly grouped into in 
vivo and in vitro studies. Using 1311 and 1251, tests have 
been designed to measure thyroid function at the 
hypothalamic, pituitary, or thyroid level and at the 
peripheral level by radioimmunoassay or radioassay 
of circulating thyroid hormones. The following 
schema of testing may be used to assess thyroid func-
tion: 
I. Hypothalamus. Following the intramuscular administra-
tion of thyrotropic-releasing hormone, the following 
changes occur in plasma thyroid-stimulating hormone 
(TSH) level, which can be measured by radioimmuno-




A. Toxic Diffuse Goiter 
B. Toxic Nodular Goiter 













II. Pituitary capability of secreting TSH under normal and 
abnormal conditions can be accurately measured by de-
termination of peripheral level of TSH using "'I radio-
immunoassay techniques. The following are TSH values 
for various thyroid disorders: 
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CONDITION TSH 
I. Normal 1-lOµU / mlt 
2. Hyperthyroidism 
A. Toxic Diffuse Goiter Normal 
B. Toxic Nodular Goiter Normal 
C. Toxic Nodule Normal 
D. Hypothalamic Increased (I) 
E. Pituitary Tumor Increased (I) 
3. Hypothyroidism 
A. Hypothalamic Low 
B. Pituitary Normal 
C. Thyroid Increased 
Ill. Assessment of thyroid glandular function can be deter-
mined by measuring the concentration of 131I using basal 
and dynamic studies fo llowing oral administration of "'I. 
l. BASAL STUDIES PERCENT 1311 CONCENTRATION 
3 hours 5 hours 24 hours 





2. DYNAMIC STUDIES 
>11.6% 
< 2.5 
A. TSH Stimulation Test 
B. T-3 Suppression 




> 50% Increase 
> 50% Decrease 
< 3% Decrease 
Determination of the circulating thyroid hor-
mones by radioassay and radioimmunoassay tech-
niques using 1251 are readily available and offer accu-
rate measurement of these hormones when properly 
performed. Normal values for the circulating hor-
mones are as follows: 
t Normal values for the Medical College of Virginia. 
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l. Total thyroxine 
2. Triiodothyronine 
3. Serum free thyroxine 
5.6-13.lµg/ dlt 
70-170 ng/ dlf 
1.2-3.5 ng/ dlt 
Discussion. Differential diagnosis of diseases of 
the thyroid can be made with a high degree of cer-
tainty using the previously mentioned tests employ-
ing radionuclides. The clinical applicability of the 
various tests is dependent upon a thorough knowl-
edge of thyroid physiology and interrelationships of 
trophic hormones and carrier proteins. A review of 
the disease states and diagnosis using specific tests 
follows. 
l. Hyperthyroidism. The vast majority of cases 
can be diagnosed on clinical grounds alone from the 
history and physical findings . Confirmation is easily 
obtained by employing the 1311 uptake at 3, 5, and 24 
hours. This will be elevated in the majority of 
hyperthyroid patients. The above-mentioned test in 
conjunction with the T-4 and serum free thyroxine 
(SFT)-4, which are usually elevated, will establish the 
diagnosis in both Graves' disease and hyperthyroidism 
due to a nodular goiter. If the diagnosis is suspected 
on clinical grounds and the above tests are normal, 
one can then perform the T-3 suppression study. This 
is done by obtaining a baseline uptake at 3, 5, and 24 
hours and then placing the patient on L-
triiodothyronine, I 50µg daily for seven days. The up-
take in the normal person is suppressed after T-3 ad-
ministration by at least 50% and is usually below 20% 
at 24 hours. Hyperthyroid patients seldom suppress 
below 20% and never below 50% of original uptake. 
The usual hyperthyroid patient has little or no change 
in 24-hour uptake following T-3. Data from our 
laboratory on T-4 and SFT-4 also reveal less than 
50% suppression in the hyperthyroid patient with the 
average change being lµg/ dl or less. In rare cases, 
thyrotoxicosis may be due to elevated T-3 levels. 
Under these circumstances, the T-4 and SFT-4 and 
uptake are normal but the latter is nonsuppressible. 
2. Hypothyroidism. In contrast to hyperthyroid-
ism, hypothyroidism is not always easy to diagnose. 
This disease has protean manifestations and may be 
insidious in onset. 
Diagnosis when hypothyroidism is suspected 
clinically is best confirmed by a 24-hour 1811 uptake of 
less than 9% in 24 hours and a low total and free 
thyroxine of less than 5.6µg/ dl and 1.2 ng/ dl, respec-
tively. 
Differentiation between pituitary or thyroid 
failure can now be made by measuring serum TSH by 
1251 radioimmunoassay following intramuscular or in-
travenous injection of thyrotropin-releasing hormone 
(TRF). A rise in the serum TSH will occur within ap-
proximately 15 to 30 minutes after intravenous injec-
tion (2) and 2 to 3 hours after intramuscular TRF (3) 
injection if the pituitary is intact. Failure to detect a 
significant rise in TSH after TRF administration im-
plies pituitary failure and hence, establishing the 
diagnosis of secondary hypothyroidism. 
3. Subacute thyroiditis. Diagnosis of subacute 
thyroiditis is usually suggested by the clinical picture 
of anterior neck pain with exacerbation on swallow-
ing or coughing, radiation of pain to the ears, 
hoarseness, and signs and symptoms of hypermetab-
olism. The thyroid is usually enlarged and especially 
tender. 
Laboratory confirmation is established by the 
presence of a low 1811 uptake at 3, 5, and 24 hours and 
an elevated T-4 and SFT-4. 
4. Enzymatic defects. These are usually charac-
terized by the presence of a goiter dating from early 
childhood or the development of thyroid enlarge-
ment following ingestion of certain drugs or foods . 
Laboratory studies usually demonstrate an 
elevated 18 11 uptake value, low total T-4 and SFT-4 
and discharge of 181 I from the thyroid gland of greater 
than 3% following oral administration of potassium 
perchlorate or potassium thiocyanate. 
5. Nodules. Adequate assessment of both single 
and multiple nodules in the thyroid gland require that 
a scan be performed after the administration of 1311 
(4), 1251 (5) if available, or 99mTc (6). The former is 
performed in our laboratory. Evaluation of nonfunc-
tioning nodules subsequently removed surgically at 
our institution over a ten-year period reveals that 
single nonfunctioning nodules were malignant in 
12.5% of cases, multiple nodules in 16.5%, with the 
total overall incidence of malignancy being 13.0% in 
nonfunctioning nodules. (These findings have been 
noted in a study by J. M . Harrison, MD, R . H . 
Kirkland, MD, and the author, unpublished data). 
Or 24 malignant nodules out of 184 nonfunction-
ing nodules by scan. 
The incidence of malignancy in hot nodules in 
the same study was I out of 74, or 1.3%. Reexamina-
tion of the scan in the one case revealed that, in 
retrospect, this most likely was a cold nodule. A 
functioning nodule is thus strong evidence against 
malignancy, although some reports of this occurring 
have appeared in the literature (7) . 
The autonomous nodule with or without 
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hyperthyroidism is characterized by uptake in the 
nodule only and suppression of the remaining thyroid 
tissue. The nodule fails to suppress following the ad-
ministration of L-triiodothyronine as previously dis-
cussed and there is no significant change in the T-4 or 
SFT-4 by 1251 radioassay. Thyroid-stimulating hor-
mone and long-acting thyroid stimulator (LATS) 
values are characteristically low for the former and 
undetectable for the latter. Autonomy can be con-
firmed by repeating the scan after administration of 
10 units of TSH. 
Conclusion. Correct assessment of thyroid func-
tion and evaluation of nodules can be obtained by the 
proper application of the appropriate in vivo or in 
vitro tests as previously discussed. Thyroid function 
can now be evaluated at the hypothalamic, pituitary, 
and thyroid level using both 1311 and 1251 and at the 
peripheral level using 1251 radioassay or radioim-
munoassay procedures. Using these procedures as 
described, quantitative evaluation of thyroid function 
can be made, and in most instances the disease 
process can be defined in a specific manner. 
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